

Marrone Bio Innovations

09:34 22 Sep 2020

Marrone Bio announces retirement of president and CFO James Boyd

Marrone Bio Innovations Inc (NASDAQ:MBII) announced Tuesday that president and chief financial officer James Boyd is retiring.

A national search process for a new CFO is underway, and Boyd will continue in both posts during the search process, the company said in a statement.

"Jim has been a key member of the senior management team and a highly-regarded leader for the company over the last seven years," said CEO Kevin Helash.

READ: Marrone Bio and Rizobacter to distribute foliar fertilizer and plant health technology in Argentina, Uruguay, Paraguay and Bolivia

"He has helped guide the company through its successful transition as a market leader in the agricultural biologicals space. On behalf of myself, the board of directors and the entire team at Marrone Bio Innovations, we want to thank Jim for his numerous contributions to the strength of the company and wish him the very best in his retirement," Helash added.

The CEO said the company is "looking for an exceptional individual to help lead the company during its next phase of accelerated growth while ensuring we are brilliant at the basics that drive operational and financial excellence."

He added: "We have a solid financial team in place and expect the new CFO to be able to make a rapid transition and add immediate value."

Boyd said he is "proud to have helped build the company into a world-class organization" with an unmatched product portfolio in sustainable biological products.

"Given our recent revenue growth and margin expansion, I am confident the company is poised to deliver meaningful shareholder value. I look forward to working with our finance team as we make this transition and ensure the company's continuing success," Boyd said.

Based in Davis, California, Marrone Bio holds more than 400 issued and pending patents and has brought six US Environmental Protection Agency-registered biological product lines and one biostimulant to market.

Contact the author: patrick@proactiveinvestors.com

Follow him on Twitter @PatrickMGraham

Price: 1.19

Market Cap: \$181.45 m

1 Year Share Price Graph



Share Information

Code: MBII

Listing: NASDAQ

52 week High Low
1.5 0.6104

Sector: Agribusiness

Website:
www.marronebioinnovations.com

Company Synopsis:

Marrone Bio Innovations Inc. (NASDAQ: MBII) is a growth company leading the movement to more a sustainable world through the discovery, development and sale of innovative biological products for crop protection, plant health and waterway systems treatment that help customers operate more sustainably while increasing their return on investment.

action@proactiveinvestors.com

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Marrone Bio Innovations named herein, including the promotion by the Company of Marrone Bio Innovations in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).